OPTIMIZATION OF PHARMACOTHERAPY IN PATIENTS WITH MULTIPLE CHRONIC DISEASES

Authors

  • Felix R. Neumann Department of Clinical Pharmacology and Therapeutics,

Keywords:

multimorbidity; polypharmacy; deprescribing; medication review; personalized pharmacotherapy; model-informed precision dosing; pharmacogenomics; clinical decision support.

Abstract

Background: Multimorbidity commonly leads to polypharmacy, fragmented prescribing, treatment burden, drug-drug interactions, prescribing cascades, and difficulty applying single-disease clinical guidelines. Pharmacotherapy optimization therefore requires a patient-centered approach that distinguishes appropriate from problematic polypharmacy and integrates evidence on medication review, deprescribing, precision dosing, pharmacogenomics, and clinical decision support. Objective: To synthesize contemporary evidence on strategies for optimizing pharmacotherapy in adults with multiple chronic diseases and to propose a practical framework for medication prioritization, individualized dosing, monitoring, and follow-up. Methods: A structured literature review was conducted using international peer-reviewed evidence and major clinical frameworks published predominantly between 2020 and 2026. Studies and guidance addressing multimorbidity, polypharmacy, medication review, deprescribing, multidisciplinary care, electronic decision support, model-informed precision dosing, therapeutic drug monitoring, and pharmacogenomics were prioritized. Results: The evidence consistently supports recurrent medication reconciliation, indication-by-indication review, identification of potentially inappropriate medicines, active deprescribing when harms outweigh benefits, shared decision-making, and explicit monitoring after regimen changes. Multidisciplinary interventions reliably improve medication appropriateness and reduce medication-related problems, although effects on mortality, hospitalization, and functional outcomes remain heterogeneous. Precision dosing and pharmacogenomic strategies can further reduce interindividual variability for selected drugs, but implementation depends on validated tools, informatics integration, and clinician expertise. Conclusion: Pharmacotherapy optimization in multimorbidity should be treated as a continuous clinical process rather than a one-time reduction in pill count. The most defensible model combines patient goals, disease priorities, medication necessity, interaction risk, organ function, adherence, evidence-based deprescribing, and precision tools within a structured follow-up cycle. (1,2,5,9,11,13)

References

1.NICE. Multimorbidity: Clinical Assessment and Management (NG56). National Institute for Health and Care Excellence; 2016, updated guidance accessed 2026.

2.Onder G, et al. Medication review and deprescribing in different healthcare settings: a position statement from an Italian scientific consortium. Drugs & Aging. 2024. PMID: 38459218.

3.Walker LE, Pirmohamed M. The status of drug evaluation in older adults in the United Kingdom: bridging the representation gap. Journal of the American Geriatrics Society. 2024;72(9):2933-2941. doi:10.1111/jgs.18817.

4.American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023;71(7):2052-2081.

5.van Poelgeest E, et al. Optimizing pharmacotherapy and deprescribing strategies in older adults living with multimorbidity and polypharmacy: EuGMS SIG on pharmacology position paper. European Geriatric Medicine. 2023;14(6):1195-1209. doi:10.1007/s41999-023-00872-0.

6.Zidan A, Awaisu A. Inappropriate polypharmacy management versus deprescribing: a review on their relationship. Basic & Clinical Pharmacology & Toxicology. 2024;134(1):6-14. doi:10.1111/bcpt.13920.

7.Streit S, et al. Optimising prescribing in older adults with multimorbidity and polypharmacy in primary care (OPTICA): cluster randomised clinical trial. BMJ. 2023;381:e074054.

8.O’Mahony D, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. European Geriatric Medicine. 2023.

9.Martínez-Velilla N, et al. Systematic review and meta-analysis on the effectiveness of multidisciplinary interventions to address polypharmacy in community-dwelling older adults. Ageing Research Reviews. 2024;98:102317. doi:10.1016/j.arr.2024.102317.

10.Clinical impact of medication review and deprescribing in older inpatients: a systematic review and meta-analysis. 2024. PMID: 38822740.

11.Minichmayr IK, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, Wicha SG. Model-informed precision dosing: state of the art and future perspectives. Advanced Drug Delivery Reviews. 2024;215:115421. doi:10.1016/j.addr.2024.115421.

12.Defining, identifying and addressing problematic polypharmacy within multimorbidity in primary care: a scoping review. BMJ Open. 2024. doi:10.1136/bmjopen-2023-081698.

13.Swen JJ, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet. 2023;401(10374):347-356. doi:10.1016/S0140-6736(22)01841-4.

14.Barriers and facilitators for bringing model-informed precision dosing to the patient’s bedside: a systematic review. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3510.

15.Interventions to optimize medication management in older adults: an umbrella review of systematic reviews. 2026. PMID: 42339921.

Published

2026-09-24